Trial Profile
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 18 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Nov 2023 Planned End Date changed from 1 Nov 2023 to 1 Dec 2023.
- 07 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Dec 2023.